• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes.

作者信息

Abrahami Devin, Douros Antonios, Yin Hui, Yu Oriana H Y, Azoulay Laurent

机构信息

Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.

出版信息

Diabetes Care. 2019 Sep;42(9):e150-e152. doi: 10.2337/dc19-0849. Epub 2019 Jul 11.

DOI:10.2337/dc19-0849
PMID:31296645
Abstract
摘要

相似文献

1
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病患者的骨折风险
Diabetes Care. 2019 Sep;42(9):e150-e152. doi: 10.2337/dc19-0849. Epub 2019 Jul 11.
2
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.钠-葡萄糖协同转运蛋白2抑制剂联合二肽基肽酶-4抑制剂治疗2型糖尿病：当前临床证据及理论依据综述
Drug Des Devel Ther. 2017 Mar 21;11:923-937. doi: 10.2147/DDDT.S121899. eCollection 2017.
3
Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.钠-葡萄糖协同转运蛋白2抑制剂在国内和国际指南中的定位
Med Clin (Barc). 2016 Nov;147 Suppl 1:49-53. doi: 10.1016/S0025-7753(17)30626-7.
4
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病管理中的作用。
Can J Diabetes. 2017 Oct;41(5):517-523. doi: 10.1016/j.jcjd.2017.08.241.
5
Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂：基于循证实践的2型糖尿病自然病程中使用方法
Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26.
6
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂与 2 型糖尿病的治疗。
Annu Rev Med. 2019 Jan 27;70:323-334. doi: 10.1146/annurev-med-042017-094221. Epub 2018 Sep 26.
7
Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病老年患者中的应用。
Geriatr Gerontol Int. 2018 Jan;18(1):108-114. doi: 10.1111/ggi.13149. Epub 2017 Sep 1.
8
Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain.在西班牙接受钠-葡萄糖协同转运蛋白2抑制剂治疗的2型糖尿病患者的临床特征及真实世界临床实践经验
Med Clin (Barc). 2016 Nov;147 Suppl 1:30-34. doi: 10.1016/S0025-7753(17)30623-1.
9
Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂治疗相关的骨折风险：一项随机对照试验的荟萃分析。
Diabetes Metab. 2019 Oct;45(5):436-445. doi: 10.1016/j.diabet.2019.01.010. Epub 2019 Feb 6.
10
Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials.钠-葡萄糖协同转运蛋白 2 抑制与肾缺血：对未来临床试验的影响。
Kidney Int. 2018 Sep;94(3):459-462. doi: 10.1016/j.kint.2018.05.026.

引用本文的文献

1
High-Dimensional Disease Risk Score for Dealing With Residual Confounding Bias in Estimating Treatment Effects With a Survival Outcome.用于处理生存结局估计治疗效果时残余混杂偏倚的高维疾病风险评分
Pharmacoepidemiol Drug Saf. 2025 Jul;34(7):e70172. doi: 10.1002/pds.70172.
2
Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.钠-葡萄糖协同转运蛋白 2 抑制剂与基于肠促胰岛素的药物治疗 2 型糖尿病与骨折风险的比较。
JAMA Netw Open. 2023 Sep 5;6(9):e2335797. doi: 10.1001/jamanetworkopen.2023.35797.
3
Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
慢性肾脏病患者中钠-葡萄糖共转运蛋白 2 抑制剂的骨折风险。
Clin J Am Soc Nephrol. 2022 Jun;17(6):835-842. doi: 10.2215/CJN.16171221. Epub 2022 May 26.
4
Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.钠-葡萄糖协同转运蛋白2抑制剂在韩国真实世界临床实践中不会增加骨折风险：一项全国性观察性队列研究。
J Diabetes Investig. 2022 Jun;13(6):986-996. doi: 10.1111/jdi.13768. Epub 2022 Mar 4.
5
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.恩格列净在常规护理患者中的疗效和安全性：来自 EMPagliflozin 比较疗效和安全性（EMPRISE）研究的结果。
Diabetes Obes Metab. 2022 Mar;24(3):442-454. doi: 10.1111/dom.14593. Epub 2021 Dec 1.
6
Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.2型糖尿病合并糖尿病肾病患者抗糖尿病药物的处方趋势：一项队列研究
Diabetes Care. 2021 Aug 3;44(10):2293-301. doi: 10.2337/dc21-0529.
7
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）暴露与2型糖尿病的结局：基于人群的观察性研究的系统评价
Diabetes Ther. 2021 Apr;12(4):991-1028. doi: 10.1007/s13300-021-01004-2. Epub 2021 Mar 4.
8
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.SGLT2 抑制剂在降低血糖之外的心脏肾脏保护作用不断扩大。
Ann Med. 2021 Dec;53(1):2072-2089. doi: 10.1080/07853890.2020.1841281.
9
Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences.钠-葡萄糖共转运蛋白 2 抑制剂的管状作用：预期和非预期的后果。
Curr Opin Nephrol Hypertens. 2020 Sep;29(5):523-530. doi: 10.1097/MNH.0000000000000632.
10
Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.恩格列净对心肌梗死后左心功能不全非糖尿病大鼠肾脏结构和功能的影响。
Cardiovasc Drugs Ther. 2020 Jun;34(3):311-321. doi: 10.1007/s10557-020-06954-6.